Cite
HARVARD Citation
Le, D. et al. (2015). Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR). Journal for immunotherapy of cancer. 3 (2), p. 1. [Online].